Zacks Research Has Positive Forecast for BHC Q3 Earnings

Bausch Health Companies Inc. (NYSE:BHC) – Research analysts at Zacks Research raised their Q3 2025 earnings per share estimates for Bausch Health Companies in a note issued to investors on Tuesday, December 17th. Zacks Research analyst R. Department now forecasts that the company will post earnings per share of $1.15 for the quarter, up from their prior estimate of $1.12. The consensus estimate for Bausch Health Companies’ current full-year earnings is $3.74 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q4 2025 earnings at $1.25 EPS.

Other equities analysts have also recently issued research reports about the company. Royal Bank of Canada raised their price objective on Bausch Health Companies from $10.00 to $11.00 and gave the company a “sector perform” rating in a report on Friday, November 1st. StockNews.com upgraded Bausch Health Companies from a “hold” rating to a “buy” rating in a research note on Friday, October 25th. Finally, Evercore ISI upgraded Bausch Health Companies to a “hold” rating in a research note on Tuesday, October 15th. One analyst has rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $7.75.

Bausch Health Companies Trading Up 1.1 %

Shares of BHC stock opened at $7.47 on Friday. The firm’s fifty day moving average price is $8.33 and its two-hundred day moving average price is $7.28. Bausch Health Companies has a 1 year low of $3.96 and a 1 year high of $11.46. The firm has a market capitalization of $2.70 billion, a P/E ratio of -15.56 and a beta of 0.69.

Bausch Health Companies (NYSE:BHC) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $1.12 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.10. The company had revenue of $2.51 billion during the quarter, compared to analysts’ expectations of $2.42 billion. Bausch Health Companies had a negative net margin of 1.88% and a negative return on equity of 755.86%. The business’s quarterly revenue was up 12.2% on a year-over-year basis. During the same period last year, the business earned $1.03 EPS.

Hedge Funds Weigh In On Bausch Health Companies

Institutional investors and hedge funds have recently modified their holdings of the business. CIBC Asset Management Inc boosted its stake in shares of Bausch Health Companies by 0.3% in the third quarter. CIBC Asset Management Inc now owns 374,729 shares of the company’s stock valued at $3,060,000 after buying an additional 1,082 shares during the period. Bfsg LLC lifted its position in shares of Bausch Health Companies by 46.7% during the 2nd quarter. Bfsg LLC now owns 11,450 shares of the company’s stock valued at $80,000 after acquiring an additional 3,643 shares during the period. Northwest & Ethical Investments L.P. grew its holdings in shares of Bausch Health Companies by 13.0% during the 3rd quarter. Northwest & Ethical Investments L.P. now owns 32,384 shares of the company’s stock worth $264,000 after purchasing an additional 3,734 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Bausch Health Companies by 6.9% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 60,706 shares of the company’s stock worth $423,000 after purchasing an additional 3,923 shares during the period. Finally, The Manufacturers Life Insurance Company raised its stake in Bausch Health Companies by 2.0% in the second quarter. The Manufacturers Life Insurance Company now owns 246,808 shares of the company’s stock valued at $1,719,000 after purchasing an additional 4,944 shares in the last quarter. 78.65% of the stock is currently owned by institutional investors and hedge funds.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.